SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 16th, 2017 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of , 2017, between Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 23rd, 2014 • Oxigene Inc • Biological products, (no disgnostic substances)
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
Exhibit 10.14 CONFIDENTIAL TREATMENT REQUESTED AS TO PORTIONS OF THIS DOCUMENT, WHICH PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURTIES AND EXCHANGE COMMISSION. TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this "Agreement") is...Termination Agreement • May 15th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New Jersey
RECITALSLease • May 3rd, 2006 • Oxigene Inc • Biological products, (no disgnostic substances)
COMMON STOCK PURCHASE WARRANT OXIGENE, INC.Security Agreement • May 23rd, 2014 • Oxigene Inc • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year and three month anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OXiGENE, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
OXiGENE, INC. COMMON STOCKUnderwriting Agreement • December 15th, 2005 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.24 OXiGENE Inc. Restricted Stock Agreement for Employees This Restricted Stock Agreement (this "Agreement") is made as of the 2nd day of January 2002, between OXiGENE Inc., a Delaware corporation (the "Company"), Frederick Driscoll...Restricted Stock Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.20 ADDENDUM TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF OCTOBER 9, 1995 This Addendum to the Executive Employment Agreement, originally dated October 9, 1995, is executed on May __,2001, to be effective on July 1, 2001, by and between OXiGENE,...Executive Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances)
COPLEY PLACE BOSTON, MASSACHUSETTS OFFICE LEASEOffice Lease • April 15th, 1998 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
December 4,2006Severance Agreement • May 7th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.13 CONFIDENTIAL TREATMENT REQUESTED AS TO PORTIONS OF THIS DOCUMENT, WHICH PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURTIES AND EXCHANGE COMMISSION. EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement") is...Employment Agreement • May 15th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 1st, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 25, 2021, by and between ONCOTELIC THERAPEUTICS, INC., a Delaware corporation, with its address at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 (the “Company”), and GENEVA ROTH REMARK HOLDINGS, INC., a New York corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).
UNDERWRITING AGREEMENTUnderwriting Agreement • October 30th, 1996 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.15 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is entered into as of October 23, 2000, between OXiGENE Inc., a Delaware corporation ("OXiGENE" or the "Company"), and Mr. Frederick W. Driscoll (the "Executive"). W I T N...Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 7th, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 3, 2021, by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”), and PEAK ONE OPPORTUNITY FUND, L.P., a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the equity purchase agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
Exhibit 4.2 OXiGENE, INC. One Copley Place, Suite 602, Boston, MA 02116 July 8, 1998 American Stock Transfer & Trust Company 6201 15th Avenue 3rd Fl. Brooklyn, New York 11219 Attn: Herb Lemmer Re: Amendment to Warrant Agreement...Warrant Agreement • July 9th, 1998 • Oxigene Inc • Biological products, (no disgnostic substances)
Reference is made to the Warrant Agreement, dated August 26, 1994 (the "Agreement"), by and between OXiGENE, Inc., a Delaware corporation (the "Company") and American Stock Transfer & Trust Company (the "Warrant Agent") in its capacity as the Company's transfer agent and warrant registrar, as amended by letter agreement dated September 19, 1994.
FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 20th, 2013 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 18, 2013, between OXiGENE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
Exhibit 10.13 EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement") is entered into as of January 2, 2002, by and between OXiGENE INC., a Delaware corporation with its principal offices at 321 Arsenal Street, Watertown, Massachusetts 02472...Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 11th, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 10, 2010, is by and among OXiGENE, Inc., a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210, South San Francisco, CA 94080 (the “Company”), and each of the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
AGREEMENTConsulting Agreement • March 30th, 2000 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.1Employment Agreement • May 7th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
WITNESSETHConsultant Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances)
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 23rd, 2014 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 22, 2014, between OXiGENE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT MATEON THERAPEUTICS, INC.Common Stock Purchase Warrant • June 13th, 2017 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT` (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 PM New York City time on , 202 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares of common stock, par value $0.01 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement') is entered into as of April 1st, 2001, between OXiGENE Inc., a Delaware corporation ("OXiGENE," or the "Company"), and Dr. David Chaplin (the "Executive"). W I T N E S S E...Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • July 11th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances)
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances)
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • May 7th, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • Nevada
This equity purchase agreement is entered into as of May 3, 2021 (this “Agreement”), by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”), and Peak One Opportunity Fund, L.P., a Delaware limited partnership (the “Investor”).
6,250,000 Units OXiGENE, INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • July 15th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
AMENDMENT TO EXECUTIVE EMPLOYMENT CONTRACTExecutive Employment Contract • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances)
This Agreement is made and entered into on July 1, 1999, by and between OXiGENE, Inc. a Delaware Corporation with its principal office at One Copley Place, Suite 602, Boston, MA 02116 ("the Company"), and Bjorn Nordenvall, Ph.D., M.D., an adult resident of Sweden ("the Executive").
OXIGENE INC. ------------Restricted Stock Agreement • March 25th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
AddendumExecutive Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances)
OXiGENE, Inc. of Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • July 21st, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
OXiGENE, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC, a Delaware limited liability company (“MLV”), as follows:
RECITALS:Employment Agreement • September 29th, 2006 • Oxigene Inc • Biological products, (no disgnostic substances)
COLLABORATIVE RESEARCH AGREEMENT -------------------------------- This agreement ("AGREEMENT") is made as of August 1, 1997 ("EFFECTIVE DATE") by and between BOSTON MEDICAL CENTER CORPORATION (hereinafter referred to as "BMCC"), a Massachusetts...Collaborative Research Agreement • April 15th, 1998 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
